Price movement over the last 24 hours
ARK Genomic Revolution ETF vs Vanguard Mega Cap Growth ETF — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Vanguard Mega Cap Growth ETF trades at $88.13. Which is the better fit depends on your goals.
| ARKG | MGK | |
|---|---|---|
Sector | Sector/Thematic | Broad Market / Factor |
52-Week High | $43.57 | $92.06 |
52-Week Low | $23.09 | $70.70 |
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
MGK, the Vanguard Mega Cap Growth ETF, trades at $89.06, up 0.52% today, with a bullish technical signal driven by moving averages. The ETF focuses on large-cap U.S. growth stocks, heavily concentrated in technology and consumer discretionary sectors. A 1:5 stock split occurred on April 21, 2026, and a $0.08 dividend is scheduled for June 30, 2026. Recent news highlights its low expense ratio of 0.05% and potential inclusion of SpaceX, enhancing its growth appeal.
Outlook remains positive due to strong mega-cap tech earnings and historical market outperformance. Key risks include high concentration in top holdings and sector-specific volatility. Investors benefit from cost efficiency and exposure to leading growth companies, but should monitor valuation levels and broader market trends for sustained gains.
Trailing returns across standard periods
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →